SCHEMBL6191766

SCHEMBL6191766

Clc1ccc(Cn2ccc3ccc(Oc4ccccc4)cc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 1/20 0.47
▸ MCL1 Q07820 2/20 0.47
▸ RHEB Q15382 1/20 0.47
▸ HTR6 P50406 2/20 0.47
▸ HDAC8 Q9BY41 2/20 0.44
▸ HDAC3 O15379 1/20 0.44
▸ HDAC4 P56524 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC7 Q8WUI4 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ HDAC10 Q969S8 1/20 0.44
▸ HDAC11 Q96DB2 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ HDAC9 Q9UKV0 1/20 0.44
▸ HDAC5 Q9UQL6 1/20 0.44
▸ NCOR2 Q9Y618 1/20 0.44
▸ APP P05067 1/20 0.43
▸ SNCA P37840 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085962 0.89 KDM4C (0.47) KDM4CRHEBHTR6HDAC8HDAC3
SCHEMBL6086767 0.84 MAPK14 (0.54) MCL1HTR6APPSNCAKMT2A
SCHEMBL6085908 0.82 HDAC8 (0.58) MCL1HTR6HDAC8HDAC3HDAC4
SCHEMBL28101302 0.79 HTR6 (0.60) HTR6APPSNCABRD4KMO
SCHEMBL6086834 0.79 KMO (0.55) HTR6HDAC8HDAC3HDAC4HDAC1
SCHEMBL28886142 0.77 HTR2A (0.57) KDM4CHTR6HDAC8HDAC3HDAC4
SCHEMBL6086725 0.76 HDAC8 (0.53) MCL1HDAC8HDAC3HDAC4HDAC1
SCHEMBL29459650 0.76 HTR6 (0.72) HTR6HDAC8HDAC3HDAC1HDAC2
SCHEMBL2247137 0.76 HTR6 (0.72) HTR6HDAC8HDAC3HDAC1HDAC2
SCHEMBL11976537 0.75 FFAR1 (0.51) MCL1RHEBHTR6HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244652-B1 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY CELL THERAPEUTICS EUROPE SRL (IT) 2005-08-24 — — EP disclosed
US-6753342-B2 ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT NOVUSPHARMA S.P.A. (IT) 2004-06-22 — — US disclosed
US-20030158153-A1 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung NOVUSPHARMA S.P.A. (IT) 2003-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158153-A1 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung IDO2, IDO1, TXNRD2 KDM4C 2743/4885MCL1 603/4885RHEB 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback